Abstract: The present disclosure provides a sensor substrate in which deterioration of a first specific-binding substance immobilized on a surface of the sensor substrate is suppressed even when the sensor substrate is washed or dried. The present sensor substrate includes a base material; a first specific-binding substance having a property of binding specifically to an analyte, the first specific-binding substance being immobilized on a surface of the base material; and a first sugar molecule. The first sugar molecule is immobilized on the surface of the base material by a chemical bond.

Abstract: Methods of and compositions for breaking down a biofilm or inhibiting, preventing or treating a microbial infection that produces a biofilm are disclosed, which involves administration of an interfering agent capable of specifically competing, titrating, or inhibiting the binding of an HU protein to a microbial DNA. By competing with HU proteins that bind to DNA scaffold in the biofilm, these interfering agents destabilize the biofilm leading to destruction and removal of the biofilm by the immune system. Further method and composition aspects are contemplated in relation to infections caused by bacteria that export an HU protein.

Abstract: Disclosed is a method for producing an antibody reagent for detecting a test substance in a sample by an immune complex transfer method. The method comprises the steps of: bringing an antibody solution comprising a labeled antibody capable of binding to the test substance into contact with a solid phase used in the immune complex transfer method; and separating the solid phase and the antibody solution to prepare the antibody reagent from the antibody solution.

Abstract: Methods, compositions, systems, and devices are provided for performing and analyzing agglutination assays. In one aspect, methods for image analysis of agglutination assays are provided. In another aspects, methods for performing agglutination assays are provided. In one aspect, the methods may be used for the detection of various molecules, including viruses or antibodies against a virus. In another aspect, the methods can be used to determine effective immunization of a subject.

Abstract: Embodiments concern constructs comprising surrogate light chain sequences. In particular, embodiments concern constructs that can bind to DR4 and/or DR5 and aspects relating to such constructs and their use.

Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.

Abstract: A solid phase reaction method comprising an elongate material of (1) with a substance provided thereon through at least one reaction zone (2) and comprises at least one group for attachment to at least one linker species of said substance. The elongate material (1) may be a cord ribbon, thread or tape.

Abstract: The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker SLIM-1, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SLIM-1 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SLIM-1 as a marker protein in the assessment of heart failure, a marker combination comprising SLIM-1 and a kit for measuring SLIM-1.

Abstract: The invention provides methods for the diagnosis and risk stratification of adverse events in post-myocardial infarction patients by means of proADM, whereby a determination of the marker pro-adrenomedullin or partial sequence or a fragment thereof or contained in a marker combination (panel, cluster) is carried out on a post-myocardial infarction patient. The invention also provides a diagnostic device and a kit for the performance of the method of the method of the invention.

Abstract: Provided herein is a new hybrid material system, mCNT, including magnetic carbon nanotubes for biological and medical sensing applications. In certain embodiments, the systems include magnetic material on the interior of carbon nanotubes (CNTs). The amount of magnetic particles inside CNTs may be such that mCNT can respond to small, low cost, portable magnet. The exterior CNT surface is kept intact for biomolecular attachments or other functionalizations. Performance enhancement with this novel material includes improved sensitivity, reduced response time, and reduced sample volume. According to various embodiments, the mCNTs are substrates for the adherence of molecules participating in these assays or as active sensing elements. Also provided are methods of fabricating two-dimensional mCNT and CNT networks on printed electrodes.

Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.

Abstract: The present invention relates to compositions and highly sensitive methods for the detection of biotechnology product residual when monitoring product carry over and/or for cleaning verification in the manufacture of biotechnology products. In particular, the present invention is directed to immunoassays wherein one or more capture antibodies, or antigen binding fragments thereof, are used to detect residuals associated with the production of biotechnology products.

Abstract: The invention is directed to methods and devices for reducing interference from heterophile antibodies in an analyte immunoassay. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with non-human IgM or fragments thereof by dissolving into said sample a dry reagent to yield a non-human IgM concentration of at least about 20 ?g/mL or equivalent fragment concentration; and (b) performing an electrochemical immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG or fragments thereof in addition to the IgM of fragments thereof.

Abstract: Provided are methods for measuring the inherent stability of intrachain disulphide-containing domains (e.g., antibody variable domains) and for optimizing the positioning of intrachain disulphide-containing domains within a protein (e.g., a multispecific binding protein, e.g., a DVD-Ig). Also provided are methods of making multispecific binding proteins (e.g., DVD-Ig molecules) comprising two or more antibody variable domains in which the antibody variable domains are optimally positioned within the multispecific binding proteins to enhance stability of the multispecific binding protein. Multispecific binding proteins optimized using the methods disclosed herein are also provided.

Abstract: A composition comprising a conjugate of an anti-idiotype antibody specifically binding to a CDR region of a parent antibody and method of using polyclonal human serum immunoglobulin of class E, G, M, or A, and the use of said composition as a standard in an immunoassay is presented.

Abstract: Compositions and methods are provided for the use of nanoparticles, which may be referred to herein as mass dots, as mass tags for probes such as antibodies, aptamers, nucleic acids, etc. in multiplexed bioassays with ICP-MS detection.

Abstract: An anchoring/capturing system for selecting or analyzing a CHO cell according to a product secreted by the CHO cell is described. The anchoring/capturing system comprises a first antibody or a first antigen-binding fragment for anchoring to the extracellular surface of the CHO cell, and a second antibody or a second antigen-binding fragment for binding the secreted product. Uses and methods involving the anchoring/capturing system are provided.

Abstract: The use of a bacterial antigen obtained from bacterial cells in the production of antibodies for immunological assays for detecting bacterial cells.

Abstract: A binding partner, especially an antibody fragment that specifically recognizes an antigen-antibody immune complex between anti-THC and THC (tetrahydrocannabinol), is disclosed. The binding partner facilitates a non-competitive homogenous immunoassay for detection of cannabis use. A test kit comprising the binding partner is also described. Preferably the immunoassay is applied for roadside testing of saliva from suspected drivers.

Abstract: The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.

Abstract: Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides.

Abstract: It is disclosed herein that antibodies specific for preproproteins or preproteins, which are synthesized by certain types of cells or tissues, can be used in immunohistochemistry assays to discriminate between the intracellular component of the protein (including the preproprotein, preprotein and/or proprotein forms of the protein) from the secreted component of the same protein. Accordingly, provided herein is an immunohistochemical method for specific detection of the intracellular form of a protein in a biological sample using an antibody specific for the preproprotein or preprotein form of the protein. In particular examples, the protein is albumin or an immunoglobulin light chain. Also disclosed herein are preproprotein-specific ore preprotein-specific antibodies that can be used to detect specific cell types, tissue lesions or other pathological foci and metastases by IHC. In particular, antibodies that specifically bind human preproalbumin, but do not bind the secreted form of albumin are disclosed.

Abstract: Devices and methods for the detection of target molecules are disclosed. Devices and methods for detecting food-borne target molecules are also disclosed.

Abstract: A binding partner, especially an antibody fragment that specifically recognizes an antigen-antibody immune complex between anti-THC and THC (tetrahydrocannabinol), is disclosed. The binding partner facilitates a non-competitive homogenous immunoassay for detection of cannabis use. A test kit comprising the binding partner is also described. Preferably the immunoassay is applied for roadside testing of saliva from suspected drivers.

Abstract: Use of a siRNA molecule selected from the group consisting of SEQ ID NO: 173 to 344 for treating a disease associated with a pathological cell population in a subject in need thereof is disclosed. Pharmaceutical compositions and articles of manufacture comprising the siRNAs are also disclosed.

Abstract: The present invention relates to a viral vector encoding for a library of antibodies or antibody fragments that are displayed on the cell membrane when expressed in a cell. The present invention provides cells comprising the viral vector nucleic acids and methods of screening the libraries for antibodies or antibody fragments with desired characteristics.

Abstract: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract: Provided are assays to measure the presence and quantity of an antibody of interest in a patient's bloodstream or other biological sample. ECL and ELISA methods, and kits for such assays, as well as anti-idiotypic antibodies provided to detect levels of the antibody in biological samples, which are from, for example, animal models and human patients.

Abstract: The invention relates generally to gelsolin binding agents (e.g., antibodies) which can bind to gelsolin polypeptides. Gelsolin binding agents of the invention are useful, alone or in combination, to detect a gelsolin polypeptide (a.k.a., the target polypeptide) in a test sample as well as to purify native gelsolin proteins. Gelsolin binding agents are also useful to diagnose, a gelsolin related medical condition in subjects in need thereof. Kits to detect gelsolin in biological samples are provided by the present invention.

Abstract: Resonant sensors, preferably having floating bilayer symmetry, and their methods of use is determining the presence, amount or binding kinetics of an analyte of interest in a test sample are disclosed. The test sample may be a liquid or gas.

Abstract: A method for removing undesired component(s) from bound desired component(s) in an analysis including: (a) providing a container having a desired component bound thereto and an undesired component; (b) dispensing wash fluid in the container at a first level sufficient to contact a portion of the bound desired component; (c) oscillating wash fluid level in the container; and (d) removing a portion of the wash fluid from the container. A method for removing undesired components from bound desired components in an analysis including steps (a) and (b) above; (c) removing the wash fluid; (d) dispensing a wash fluid at a subsequent level lower than the first level and sufficient to wash the bound desired substrate; and (e) removing wash fluid. Preferably, the desired component is an analyte being measured.

Abstract: A method of treating cancer in a subject in need thereof is disclosed. The method comprises administering to the subject a siRNA molecule capable of inducing degradation of an mRNA encoding a polypeptide of SEQ ID NO: 1 in cells of the cancer thereby treating the cancer in the subject.

Abstract: The invention provides methods for detecting interactions between phage and antigen or antigen and antibody using biosensors.

Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof that bind naturally occurring human MAdCAM, wherein said naturally occurring human MAdCAM comprises a polypeptide with at least 90% sequence identity to SEQ ID NO:2 or SEQ ID NO:4, said naturally occurring human MAdCAM binds ?4?7, and wherein said isolated antibodies and antigen-binding fragments thereof inhibit binding of said naturally occurring human MAdCAM to human ?4?7, and wherein said antibody inhibits adhesion of RPMI 8866 cells to cells that express said human MAdCAM.

Abstract: A biosensor based upon a vertically emitting, distributed feedback (DFB) laser is disclosed. In one configuration, the DFB laser comprises a replica-molded, one- or two-dimensional dielectric grating coated with a laser dye-doped-polymer as the gain medium. A sensor is also described in which the grating layer and the active layer are combined into a single layer. DFB lasers using an inorganic or organic thin film with alternating regions of high and low index of refraction as the active layer are also disclosed. The sensor actively generates its own narrowband high intensity light output without stringent requirements for coupling alignment, thereby resulting in a simple, robust illumination and detection configuration.

Abstract: The present invention relates to antibodies, binding portions thereof, or probes that bind specifically to glucosyltransferase enzymes, and uses of these agents for detecting glucosyltransferase enzyme(s) in a sample and for diagnosing predisposition of a human child to early childhood caries. The present invention also relates to a kit for detecting a glucosyltransferase enzyme in an oral sample from an animal.

Abstract: The disclosed invention relates to monoclonal antibodies (MAbs) which recognize human fatty acid synthase (hFAS) and are distinct from previously known anti-hFAS antibodies. Compositions, devices and kits comprising the MAbs are provided along with methods of using the MAbs in a variety of applications.

Abstract: The present invention provides novel microfluidic devices and methods for performing pulsed field mobility shift assays in microfluidic devices. In particular the devices and methods of the invention utilize differences between electrophoretic mobilities (e.g., as between reactants and products, especially in non-fluorogenic reactions) in order to separate the species and thus analyze the reaction.

Abstract: The present invention relates to an enriched fish food product comprising a binder resin and a fermented soy nutraceutical. Optionally the nutraceutical may contain enzymes or coenzymes. Also, the enriched fish food product may be formed by mixing a resin with the fermented soy nutraceutical in a heated molding machine and subjecting said product to a variety of size reduction processes. For example, the fish food product may be provided in the form of a flake.

Abstract: Devices and methods for the detection of antigens are disclosed. Devices and methods for detecting food-borne pathogens are disclosed.

Abstract: A method for determining the risk of an individual of suffering from inflammation, opportunistic infection or disruption of immunoglobulin metabolism, comprising (a) determining the level of fragmentation or modification of Fc function of immunoglobulins in a sample taken from the individual and (b) determining thereby the risk of inflammation, impaired immune response or opportunistic infection. The invention also provides the use of a trypsin inhibitor in the manufacture of a medicament for use in the treatment or prevention of a disorder associated with elevated trypsin activity which is correlated with IgG fragmentation or modification.

Abstract: The present invention provides a method for diagnosis or prognosis of IgA nephropathy in a subject based on detection of the expression level of one or more biomarker genes selected from the group consisting of thymosin ?4 (Tmsb4), serine or cysteine proteinase inhibitor clade E member 2 (Serpine2), secreted phosphoprotein 1 (OPN), butyrophilin-like-2 (BTNL2), S100 calcium binding protein A8 (S100A8), Cystatin C (CysC), and any combination thereof.

Abstract: The detection of endothelial cell antibodies has been proven clinically important for successful organ transplantation. Disclosed are methods of isolating Tie-2+ and CD34? precursor endothelial cells for use in donor-specific crossmatching.

Abstract: The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating inflammatory bowel disease (IBD) and methods of treating enterobacterial infections using anti-flagellin antibodies in humans, other animals and birds.

Abstract: An apparatus and methods for binding an analyte of interest in a sample are provided. The apparatus comprises a substrate with an exposed surface with an compound, that is electrostatically charged or capable of forming hydrogen bonds, provided bound to the solid substrate. A recombinant single chain antibody (scFv) molecule specific for the analyte of interest, having one or more amino acids with charged or hydrogen-bond forming sidechains in a linker polypeptide portion, is bound to the layer on the solid substrate. When the analyte of interest is present in the sample the scFv binds the analyte to the solid substrate. The apparatus can be used with an immunoglobulin layer to detect Fc receptors, so as to detect microorganisms such as Staphylococcus aureus having protein A or protein G.

Abstract: The invention involves a method for measuring phosphorylation of proteins at specific sites and, as such, is an indicator of the protein kinase activity of enzymes capable of phosphorylating those sites. The method involves the in vitro or in vivo phosphorylation of a target protein at a specific serine, threonine or tyrosine residue, subjecting that protein (non-phosphorylated) to reaction mixture containing all reagents, including phosphokinase which allow the creation of a phosphorylated form of protein. The phosphorylated protein is measured by contacting it with an antibody specific for the phosphorylation site(s). The invention includes antibodies useful in practicing the methods of the invention. The invention particularly relates to all proteins modified by phosphorylation and dephosphorylation as illustrated by Tau, Rb and EGFR proteins and antibodies specific for the site of phosphorylation of the Tau, Rb or EGFR proteins.

Abstract: The invention concerns constructs and libraries comprising antibody surrogate light chain sequences. In particular, the invention concerns constructs comprising VpreB sequences, optionally partnered with another polypeptide, such as, for example, antibody heavy chain variable domain sequences, and libraries containing the same.

Abstract: A method of in situ immunohistochemical analysis of a biological sample is provided. The method allows for the multiplex and simultaneous detection of multiple antigens, including multiple nuclear antigens, in a tissue sample.

Abstract: The present invention relates to a method for providing molecules that are capable of inhibiting angiogenesis, comprising the steps of providing a range of molecules; testing whether these molecules can prevent interaction between JAM-B and JAM-C; testing the positive molecules for their ability to block angiogenesis in vivo; and selecting molecules that are positive in the angiogenesis test as angiogenesis inhibiting molecules. The method may further comprise the step of isolating or producing the angiogenesis inhibiting molecules. The invention further relates to the angiogenesis inhibiting molecules thus provided and produced, to their use in the treatment of cancer, to therapeutical compositions comprising them. In a particular embodiment the invention relates to monoclonal antibodies, in particular Mab H33, to soluble JAM-C and JAM-B and to small molecules.

Abstract: Ligand Drug conjugate compounds comprising a ?-glucuronide-based linker and methods of using such compounds are provided.